Jammu Journal

Diabetic Retinopathy Market Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – Genentech, Roch, Ocuphire

 Breaking News
  • No posts were found

Diabetic Retinopathy Market Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – Genentech, Roch, Ocuphire

September 23
01:04 2023
Diabetic Retinopathy Market  Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies - Genentech, Roch, Ocuphire
DelveInsight Business Research LLP
DelveInsight’s ‘Diabetic Retinopathy–Market Insights, Epidemiology, and Market Forecast—2032’ report delivers an in-depth understanding of Diabetic retinopathy, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s Diabetic Retinopathy–Market Insights, Epidemiology, and Market Forecast—2032 report delivers an in-depth understanding of Diabetic retinopathy, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Key Highlights for Diabetic Retinopathy Market 

  • Key Companies working on the Diabetic Retinopathy Market include Genetech, Roch, Ocuphire and many others 

  • Key Therapies included in the Diabetic Retinopathy Market market include OPT-302, RGX 314, Runcaciguat, and many others 

Diabetic Retinopathy Market Overview

Diabetic Retinopathy is a common and specific microvascular complication of diabetes and remains the leading cause of preventable blindness in working-aged people. It is identified in a third of people with diabetes and is associated with an increased risk of life-threatening systemic vascular complications, including stroke, coronary heart disease, and heart failure. In the USA, an estimated 40% (8% for vision-threatening retinopathy) of people with type 2 diabetes and 86% (42%) with type 1 diabetes have diabetic retinopathy.

Several large studies have shown that the onset of Diabetic Retinopathy is generally not observed within the first 5 years after the diagnosis of type 1 diabetes. In contrast, the commencement of type 2 diabetes is often more insidious, and as such, the retinal disease may be present at the time of diagnosis. Therefore, screening for Diabetic Retinopathy is recommended at the time of diagnosis in type 2 diabetics. Chronic hyperglycemia and its cardinal parameter, HbA1c, have been directly linked to DR. In this regard, the ophthalmologist plays an essential role by screening patients with diabetes mellitus, motivating them to control their glucose levels, and explaining the sequelae of DR progression, including visual impairment.

Diabetic Retinopathy Market  Epidemiology Insights

  • The total Diabetic Retinopathy prevalent cases in the 7MM were 12,585,769 in 2021.

  • In 2021, the Diabetic Retinopathy market size in the seven major markets was found to be USD 126,851 million, which is expected to grow by 2032.

Click here to learn more about the Diabetic Retinopathy Market Landscape

 The Report Covers the Diabetic Retinopathy Market Epidemiology Segmented by:

  • Diabetic Retinopathy prevalent cases 

  • Diabetic Retinopathy incident cases 

  • Diabetic Retinopathy treatment cases 

  • Diabetic Retinopathy diagnosed cases 

Diabetic Retinopathy Market Market Outlook 

The Diabetic retinopathy market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Diabetic retinopathy market trends by analyzing the impact of current therapies on the market, Diabetic Retinopathy unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Diabetic retinopathy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other Diabetic retinopathy therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Diabetic retinopathy market in 7MM is expected to change in the study period 2019–2032.

Key Companies Working in the Diabetic Retinopathy Market 

  • Genetech

  • Roch

  • Ocuphire 

And many others 

 Diabetic Retinopathy Market Therapies Covered and Analyzed in the Report

  • OPT-302

  • RGX 314

  • Runcaciguat

And many others 

 Learn more about the Key Companies and Emerging Therapies in the Diabetic Retinopathy Market Market

Table of Contents 

  1.  Key Insights 

  2.  Diabetic Retinopathy Market  Introduction 

  3.  Executive Summary of Diabetic Retinopathy Market            

  4.  Disease Background and Overview

  5.  Epidemiology and patient population

  6.  Diabetic Retinopathy Market  Emerging Therapies

  7.  Diabetic Retinopathy Market  Market Outlook

  8.  Market Access and Reimbursement of Therapies

  9.  Market Drivers 

  10.  Market Barriers 

  11.  Appendix

  12.  Report Methodology

  13.  DelveInsight Capabilities

  14.  Disclaimer

Learn about the detailed offerings of the report @ Diabetic Retinopathy Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services